PIM1 and plasma cell myeloma: Since bortezomib inhibition strongly increases the accumulation of catalytically active PIM2 [87], this finding provides a strong rationale for combining PIM inhibitors with current commonly used anti-myeloma agents or with other pathway inhibitors, including PI3K/AKT/mTOR and MAPK/ERK inhibitors to overcome drug resistance.